FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications
DelveInsight's ' FTase Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 ' report delivers a comprehensive analysis of the FTase Inhibitor market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key Takeaways
Market size projection: As per DelveInsight's analysis, the total market size of FTase inhibitors in the 7MM is expected to surge significantly by 2034, driven by expanding applications in oncology and rare genetic disorders.
Patient population data: The report provides the total FTase inhibitor potential pool, including Progeria cases occurring in approximately 1 in every 4 million live births worldwide and around 900K new head and neck squamous cell carcinoma cases each year.
Key companies: Leading FTase inhibitor companies, such as Sentynl Therapeutics (formerly Eiger BioPharmaceuticals), Kura Oncology, and others are profiled.
FTase Inhibitors Pipeline assets: Some of the key FTase inhibitor pipeline assets include tipifarnib in HRAS-mutant HNSCC and novel combination regimens with PI3Kα inhibitors.
In March 2025, significant study published research on the highly active FTase peptide inhibitor PD083176 (d2,d3,d5) for treating acute liver failure (ALF), demonstrating that this optimized FTase inhibitor could attenuate ALF progression by modulating PANoptosis.
Another research puslished in January 2025 demonstrated that lonafarnib (LNF), an approved oral FTase inhibitor, shows promise as an antiviral treatment against SARS-CoV-2.
January 2024: ZOKINVY (lonafarnib) secured marketing approval in Japan via Eiger BioPharmaceuticals and partner AnGes Inc.
May 2024: Sentynl Therapeutics closed the acquisition of the ZOKINVY program from Eiger BioPharmaceuticals.
Discover recent advancements in the FTase Inhibitor landscape @ FTase Inhibitor Recent Developments.
FTase Inhibitors Market Dynamics
The FTase inhibitors market currently represents a niche yet high-growth segment within targeted therapeutics. As of 2025, the market remains modest in size, primarily anchored by ZOKINVY's orphan-disease indications, but is poised for expansion through oncology applications. FTase Inhibitors market momentum is propelled by validated survival benefits in ultra-rare progeroid laminopathies and emerging data in HRAS-driven cancers. Scientific rationale for FTase inhibition stems from the blockade of protein farnesylation, notably of progerin in HGPS and HRAS in HNSCC, disrupting aberrant cell signaling and proliferation.
The FTase Inhibitors clinical development activity is robust, with tipifarnib advancing through Phase II/III trials both as monotherapy and in combination with Novartis's alpelisib. Additional early-stage candidates are exploring synergistic strategies to overcome resistance via dual prenylation pathway targeting.
The FTase Inhibitor competitive landscape features established biotech players, with strategic alliances and licensing deals facilitating access to novel mechanisms and patient populations. For example, the Sentynl–AnGes partnership accelerated ZOKINVY's geographic reach, while Kura Oncology's collaborations underpin its oncology pipeline.
FTase Inhibitors market barriers include compensatory prenylation pathways (geranylgeranylation) that may attenuate FTase inhibitor efficacy, and the ultra-orphan status limiting commercial scale. However, opportunities abound in biomarker-driven patient selection, combination regimens to deepen responses, and expansion into other RAS-dependent malignancies. Future outlook is characterized by anticipated label extensions, pipeline maturation, and reimbursement shifts as payers recognize the value of targeted disruption of oncogenic and progeroid pathways.
Download the FTase Inhibitor Market report to understand which factors are driving the therapeutic market @ FTase Inhibitor Market Trends.
FTase Inhibitors Targeted Patient Pool
FTase inhibitors address indications such as progeroid laminopathies and head and neck squamous cell carcinoma. Epidemiology segmentation reveals that Hutchinson-Gilford Progeria Syndrome occurs in approximately 1 in 4 million live births, yielding around 400 affected children and young adults globally.
Conversely, HNSCC accounts for roughly 890,000 new cases and 450,000 deaths annually worldwide. The total eligible patient pool for FTase inhibitors thus spans ultra-rare genetic disease patients and a subset of HRAS-mutant HNSCC. Real-world treated cases remain limited in progeria due to recent approvals, whereas oncology uptake is emerging in biomarker-enriched cohorts. Geographic segmentation shows the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan as primary markets, with forecasted growth over the 2020–2034 period driven by regulatory approvals, improved diagnostics, and expanded trial enrollment.
Discover evolving trends in the FTase Inhibitor patient pool forecasts @ FTase Inhibitor Patient Pool Analysis.
Key FTase Inhibitors Companies and Treatment Market
The FTase inhibitors treatment landscape is anchored by ZOKINVY (lonafarnib), the first FDA-approved therapy for HGPS and processing-deficient progeroid laminopathies, now commercialized by Sentynl Therapeutics. Current treatment options for progeria are limited to lonafarnib, supplemented by supportive care measures. In oncology, no FTase inhibitor is yet approved, but tipifarnib (Kura Oncology) is in late-stage trials for HRAS-mutant HNSCC, both as monotherapy and in combination with alpelisib.
Key FTase Inhibitors companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), and strategic collaborators like Novartis (alpelisib combinations) and AnGes Inc. (Japan licensing). Market positioning for FTase inhibitors hinges on their unique mechanism of action, blocking prenylation to impair oncogenic signaling and progerin accumulation. Development milestones encompass ZOKINVY's 2020 FDA approval, its January 2024 Japanese approval, and its May 2024 acquisition by Sentynl. Kura Oncology's tipifarnib recently reported promising Phase II responses in HRAS-driven cohorts, earning Breakthrough Therapy Designation in select indications. Commercial arrangements include licensing of lonafarnib in Asia and co-development agreements for oncology combinations, underscoring the collaborative strategies propelling the FTase inhibitors market forward.
Delve deeper into the major and specialised companies in the FTase Inhibitor market @ FTase Inhibitor Competitive Landscape.
Conclusion
The FTase inhibitors market is at an inflection point, transitioning from a rare-disease focus to broader oncology applications. With established clinical benefits, a robust pipeline, and strategic partnerships, FTase inhibitors are set to redefine treatment paradigms for progeroid disorders and HRAS-driven cancers through 2034 and beyond.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of FTase Inhibitor
4. Key Events
5. FTase Inhibitor Epidemiology Market Forecast Methodology
6. FTase Inhibitor Market Overview at a Glance in the 7MM
7. FTase Inhibitor: Background and Overview
8. Epidemiology and FTase Inhibitor Patient Population in Different Indications
9. FTase Inhibitor Target Patient Pool
10. FTase Inhibitor Marketed Therapies
11. FTase Inhibitor Emerging Therapies
12. FTase Inhibitor: Seven Major Market Analysis
13. FTase Inhibitor SWOT Analysis
14. KOL Views
15. FTase Inhibitor Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a few seconds ago
- CTV News
‘Great war chest of ability': Linamar CEO highlights diversity as part of portfolio growth
Jim Jarrell, CEO and President of Linamar Corporation, joins BNN Bloomberg to discuss the company's outlook as well as its growth opportunities. The president and CEO of a Canadian advanced manufacturing company says it's important to service diversified markets and industries to handle uncertain economic times, such as the ongoing trade war between Canada and the U.S., with confidence. Guelph-based Linamar Corporation offers products for mobility and industrial sectors, creating parts for agricultural producers, medical professionals and electrical vehicle developers. 'To me, I think diversity adds strength, I think like for all of us in Canada, it's the same thing,' Jim Jarrell told BNN Bloomberg Thursday morning. 'Diversity. We've now found out with the U.S., we need to make a deal with them, but we also have to think for the future and diversify our portfolio to the whole world. That's sort of what our plant at Linamar is. To make sure you're diversified and can handle the uncertainty times and you got to navigate through those with confidence.' The company reported net earnings of $126.9 million in its second quarter, down from $174.1 million a year earlier, according to a news release. The company states earnings amounted to $2.12 per diluted share down from $2. 'Our mobility came front and centre, while our industrial was down a little bit,' said Jarrell. 'That balancing act takes place nicely. A couple of years ago it was the opposite side.' Sales totalled $2.6 billion during the quarter, down from $2.8 billion the year before. The company reported free cash flow of $177.6 million, up $110.5 million from the year before. Linamar closed in on mergers and acquisitions with companies facing distress to enhance its operations and cater to new audiences around the world. Linamar acquired Bourgault Industries Ltd. in 2024, American automotive supplier Dura Shiloh in 2023 and the Salford Group in 2022. It also developed Linamar MedTech in 2022. Jarell said a lot of distressed companies Linamar has acquired have put in too much capital and are now underperforming financially. 'They need to get support,' said Jarrell. 'What we've been able to do is jump in and create a long-term sustainable company, and we do have to fix it. We have to go in and fix it, and you have to work with your customers to fix that and come up with commercial arrangements that make sense for a long-term survivable company. There is absolutely no shortage of these opportunities out there and our customers are coming to us because, again, there is a strong balance sheet. Free cash flow in the quarter of $180 million, which is fantastic. We have a great war chest of ability to do this.' He said the company, and it's acquired subsidiaries in Canada and America, remains largely unaffected by tariffs as it is compliant with Canada-United States-Mexico Agreement (CUSMA). Linamar also sources material close to its factories. He did however acknowledge it can be hard to anticipate what could come next. 'I would say predicting the future on this is extremely difficult, because it changes day to day,' said Jarrell.'I think from the mobility side, or the automotive parts industry, my analogy is sort of like an omelet. To unscramble an omelet in this North American three-way parts distribution would be very difficult and very complex to add a tariff into that system. I think it would bring the mobility industry to a halt in a very quick period, just because that supply chain just can't afford that. I think there's been a lot of lobbying on the auto parts side that I think there's a clear understanding from the administration, why that wouldn't be a smart thing to do.
Globe and Mail
31 minutes ago
- Globe and Mail
Can ExxonMobil's Low Carbon Drive Power Its Future?
Exxon Mobil Corporation XOM has integrated its low-carbon strategy into its core operations. It aims for net-zero (Scope 1 & 2) emissions from operated assets (by 2050) and Permian operations (by 2030). The company plans to invest a solid $30 billion in Lower Carbon Solutions during 2025-2030, focused on carbon capture and storage (CCS), low-carbon hydrogen and ammonia. Following the Denbury acquisition, ExxonMobil now controls more than 1,500 miles of CO2 pipelines — the largest CO2 pipeline network in the United States — and says its solutions could help reduce third-party emissions by over 50 MTA (million tons annum) by 2030. XOM also notes contracts that could enable up to 16 MTA of capture or transport by 2030. At Baytown, TX, ExxonMobil plans to install a world-scale low-carbon hydrogen plant capable of producing up to 1 Bcf/d of hydrogen, with over 98% of associated CO2 captured and up to 10 MTA of CO2 handled via CCS. The portfolio also includes lithium development in Arkansas, aiming for first production in 2027 and supplying approximately 1 million EVs/year by 2030. CVX & SHEL's Commitment to Net-Zero Pathways Like XOM, Chevron CVX and Shell plc SHEL also commit to advance low-carbon initiatives. Chevron has committed $10 billion through 2028 to advance low-carbon initiatives spanning biofuels, hydrogen, RNG and CCS. Its targets include producing 100,000 bpd of renewable fuels, 40,000 MMBtu/day of RNG and capturing 25 MTA of CO2. The company is also innovating via a $500 million energy-tech venture fund (Future Energy Fund III) to back novel decarbonization technologies. Shell is taking a parallel path, investing in renewable power, hydrogen, and large-scale CCS hubs, such as the Northern Lights project in Norway. The company aims to invest $10-$15 billion between 2023 and 2025 in low-carbon energy, focusing on electric vehicle charging, renewable power and hydrogen infrastructure. XOM's Price Performance, Valuation & Estimates Shares of XOM have lost 9.4% over the past year compared with the industry 's 3.6% decline. From a valuation standpoint, XOM trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 6.92X. This is above the broader industry average of 4.27X. The Zacks Consensus Estimate for XOM's 2025 earnings has been revised upward over the past 30 days. ExxonMobil currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Shell PLC Unsponsored ADR (SHEL): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
an hour ago
- Globe and Mail
Affirm's Expanded Stripe Partnership to Boost In-Store BNPL
Affirm Holdings, Inc. AFRM has recently expanded its partnership with Stripe to become the first buy now, pay later ('BNPL') provider to be directly integrated into Stripe Terminal, the point-of-sale (POS) system used by more than a million in-store locations across the United States and Canada. This means shoppers paying in physical stores through Stripe's POS devices can now choose Affirm at checkout. Customers can scan a QR code, complete a quick eligibility check, and select repayment terms ranging from one month to 60 months for purchases from $35 to $30,000, escaping any late or hidden fees. This is important because physical stores still witness more than 80% of retail spending, even in a digital-first era. While BNPL's biggest adoption has mostly been in online purchases, the latest deal will help AFRM penetrate in-person transactions. By embedding directly into Stripe's POS system, Affirm gains instant access to Stripe's large retail footprint in the two countries. For Stripe, adding Affirm makes its offerings more competitive to merchants seeking flexible payment options that can boost conversion rates and average order values. The move will likely increase Affirm's transaction volume and merchant adoption without heavy integration costs. Its total transactions surged 45.6% year over year to 31.3 million in the last reported quarter. Meanwhile, Stripe will likely benefit from higher merchant retention and potential increases in payment processing volume as customers opt for larger purchases financed over time. Also, both companies can tap into cross-selling opportunities. How are Other BNPL Providers Faring? AFRM's peers like PayPal Holdings Inc. PYPL and Block, Inc. XYZ are increasing their BNPL footprints throughout North America and globally. In the second quarter, PayPal's total payment volume grew 6% to $443.5 billion. Its active accounts gained 2% during this time to 438 million. PayPal's transaction revenues increased 4% year over year in the second quarter. Meanwhile, Block's BNPL platform's Gross Merchandise Value grew 17% year over year to $9.11 billion. During the quarter, Block witnessed its BNPL gross profit jump 22% to $268 million. Its post-purchase BNPL options will likely boost Cash App Card figures. Affirm's Price Performance, Valuation and Estimates Shares of Affirm have gained 27.6% year to date, outperforming the broader industry and the S&P 500 Index. Affirm'sYTD Price Performance From a valuation standpoint, Affirm trades at a forward price-to-sales ratio of 6.23X, up from the industry average of 5.84. AFRM carries a Value Score of F. The Zacks Consensus Estimate for Affirm's fiscal 2025 earnings implies a 103% improvement year over year, followed by massive growth next year. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Affirm Holdings, Inc. (AFRM): Free Stock Analysis Report Block, Inc. (XYZ): Free Stock Analysis Report This article originally published on Zacks Investment Research (
